Vanguard Group Inc. Has $70.12 Million Stock Holdings in Amphastar Pharmaceuticals, Inc. $AMPH

Vanguard Group Inc. trimmed its holdings in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 2.1% in the third quarter, according to its most recent filing with the SEC. The firm owned 2,631,040 shares of the company’s stock after selling 55,910 shares during the period. Vanguard Group Inc. owned approximately 0.06% of Amphastar Pharmaceuticals worth $70,117,000 as of its most recent filing with the SEC.

Several other institutional investors have also made changes to their positions in the business. Denali Advisors LLC bought a new stake in Amphastar Pharmaceuticals in the third quarter valued at about $3,598,000. Assetmark Inc. raised its position in Amphastar Pharmaceuticals by 29.1% in the third quarter. Assetmark Inc. now owns 56,487 shares of the company’s stock worth $1,505,000 after purchasing an additional 12,721 shares in the last quarter. Public Sector Pension Investment Board lifted its stake in Amphastar Pharmaceuticals by 11.4% during the third quarter. Public Sector Pension Investment Board now owns 139,675 shares of the company’s stock worth $3,722,000 after purchasing an additional 14,312 shares during the period. Illinois Municipal Retirement Fund lifted its stake in Amphastar Pharmaceuticals by 4.1% during the third quarter. Illinois Municipal Retirement Fund now owns 20,747 shares of the company’s stock worth $553,000 after purchasing an additional 810 shares during the period. Finally, LSV Asset Management boosted its holdings in Amphastar Pharmaceuticals by 69.7% during the third quarter. LSV Asset Management now owns 73,300 shares of the company’s stock valued at $1,953,000 after purchasing an additional 30,100 shares in the last quarter. 65.09% of the stock is currently owned by institutional investors and hedge funds.

Amphastar Pharmaceuticals Price Performance

Shares of Amphastar Pharmaceuticals stock opened at $19.34 on Friday. The company has a current ratio of 4.02, a quick ratio of 2.90 and a debt-to-equity ratio of 0.77. The stock has a market capitalization of $877.46 million, a price-to-earnings ratio of 9.53, a P/E/G ratio of 1.50 and a beta of 0.93. Amphastar Pharmaceuticals, Inc. has a 1-year low of $18.93 and a 1-year high of $31.26. The firm’s 50-day moving average price is $26.57 and its two-hundred day moving average price is $26.66.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its earnings results on Thursday, February 26th. The company reported $0.73 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.97 by ($0.24). The firm had revenue of $183.11 million during the quarter, compared to the consensus estimate of $190.48 million. Amphastar Pharmaceuticals had a net margin of 13.63% and a return on equity of 17.58%. On average, equities analysts predict that Amphastar Pharmaceuticals, Inc. will post 3.49 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Amphastar Pharmaceuticals news, Director Floyd F. Petersen sold 2,426 shares of the business’s stock in a transaction on Friday, December 12th. The stock was sold at an average price of $25.92, for a total value of $62,881.92. Following the transaction, the director owned 71,368 shares of the company’s stock, valued at approximately $1,849,858.56. The trade was a 3.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Rong Zhou sold 9,787 shares of the business’s stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $26.20, for a total value of $256,419.40. Following the completion of the transaction, the executive vice president directly owned 138,043 shares in the company, valued at approximately $3,616,726.60. This represents a 6.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 13,950 shares of company stock worth $363,925. 27.50% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on AMPH. Barclays initiated coverage on Amphastar Pharmaceuticals in a research note on Tuesday, December 9th. They issued an “equal weight” rating and a $30.00 price objective on the stock. Wells Fargo & Company cut their target price on Amphastar Pharmaceuticals from $34.00 to $30.00 and set an “overweight” rating for the company in a research report on Friday, February 27th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Amphastar Pharmaceuticals in a research note on Monday, December 29th. Zacks Research cut Amphastar Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 14th. Finally, Needham & Company LLC dropped their price objective on Amphastar Pharmaceuticals from $34.00 to $30.00 and set a “buy” rating for the company in a research note on Friday, February 27th. Two analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, Amphastar Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $29.50.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.